North Central London
Joint Formulary
 
back
8 Malignant disease and immunosuppression

The formulary for systemic anti-cancer treatments should be viewed alongside the 'National Cancer Drugs Fund list'

https://www.england.nhs.uk/publication/national-cancer-drugs-fund-list/

08-02-04 Other immunomodulating drugs

Alemtuzumab Lemtrada®
Restricted

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
  • RFL:
    • As per NICE TA
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Non-formulary
Link  NICE TA312: Alemtuzumab for relapsing‑remitting multiple sclerosis
 

Restricted Drug GP - Red View adult BNF  View SPC online  View childrens BNF
Canakinumab
Restricted

Provider notes

  • RFL:
    • Approved for use by Professor Hawkins
Link  NICE TA281 (not recommended): Canakinumab for treating gouty arthritis attacks and reducing the frequency of subsequent attacks (terminated appraisal)
Link  NICE TA302 (not recommended): Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal)
 

Restricted Drug View adult BNF  View SPC online  View childrens BNF  HCD
Cladribine tablets Mavenclad®
Restricted

Provider notes

  • RFL:
    • As per NICE TA
Link  NICE TA493: Cladribine tablets for treating relapsing–remitting multiple sclerosis
 

Restricted Drug GP - Red View adult BNF  View SPC online  View childrens BNF
Cobimetinib
Formulary

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
Link  NICE TA414 (not recommended): Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
 

View adult BNF  View SPC online  View childrens BNF
Daclizumab
Restricted

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
Link  NICE TA441 : Daclizumab for treating relapsing–remitting multiple sclerosis
 

Restricted Drug GP - Red View adult BNF  View SPC online  View childrens BNF
Daratumumab injection
Restricted

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • As per NICE TA
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • As per NICE TA
Link  NICE TA454 (not recommended): Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)
Link  NICE TA510: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
Link  NICE TA573: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
 

Restricted Drug View adult BNF  View SPC online  View childrens BNF  CDF
Dimethyl fumarate Tecfidera®
Restricted

DO NOT CONFUSE Tecfidera® AND Skilarence® AS THEY ARE LICENSED FOR DIFFERENT INDICATIONS

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
    • Check MHRA Drugs Safety Updates
  • RFL:
    • As per NICE TA
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
Link  NICE TA320: Dimethyl fumarate for multiple sclerosis
 

Restricted Drug View adult BNF  View SPC online  View childrens BNF  HCD
Fingolimod
Formulary

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
    • Check MHRA Drug Safety Updates
  • RFL:
    • As per NICE TA
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
Link  NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis
 

GP - Red View adult BNF  View SPC online  View childrens BNF  HCD
Lenalidomide 
Restricted

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines. 
    • All prescriptions must be accompanied by a prescription authorisation form
    • See links below
    • Check MHRA Drug Safety Update
  • RFL:
    • As per NICE TAs
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system). Additionally for in-patients this drug must be prescribed on an in-patients prescription chart (paper or electronic)
    • Patient, prescriber and supplying pharmacy must comply with a pregnancy prevention programme
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
Link  NICE TA171: Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy
Link  NICE TA322: Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality
Link  NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
Link  NICE TA586: Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib
Link  NICE TA587: Lenalidomide plus dexamethasone for previously untreated multiple myeloma
 

Restricted Drug GP - Red View adult BNF  View SPC online  View childrens BNF  HCD  CDF
Nintedanib  Vargatef®
Restricted

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • To be prescribed Oncology Consultants ONLY.
    • See links below
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patients prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
Link  NICE TA347: Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer
 

Restricted Drug View adult BNF  View SPC online  View childrens BNF
Nivolumab injection
Restricted

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
    • TA400, TA417 and TA530 do not apply at NMUH as service is not offered
  • RFL:
    • As per NICE TA
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • See links below
Link  NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma
Link  NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
Link  NICE TA417: Nivolumab for previously treated advanced renal cell carcinoma
Link  NICE TA462: Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma
Link  NICE TA483: Nivolumab for previously treated squamous non-small-cell lung cancer
Link  NICE TA484: Nivolumab for previously treated non-squamous non-small-cell lung cancer
Link  NICE TA490: Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy
Link  NICE TA530 (not recommended): Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy
Link  NICE TA558: Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease
Link  NICE TA581: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma
 

Restricted Drug View adult BNF  View SPC online  View childrens BNF  HCD  CDF
Ocrelizumab injection
Formulary

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
  • RFL:
    • As per NICE TA
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
Link  NICE TA533: Ocrelizumab for treating relapsing–remitting multiple sclerosis
Link  NICE TA585: Ocrelizumab for treating primary progressive multiple sclerosis
 

View adult BNF  View SPC online  View childrens BNF
Olaparib
Restricted

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
Link  NICE TA381: Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy
 

Restricted Drug View adult BNF  View SPC online  View childrens BNF  HCD
Osimertinib
Formulary

Provider notes

  • NMUH:
    • Positive NICE TA This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
  • RFL:
    • As per NICE guidance
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patients prescription chart (paper or electronic)
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
Link  NICE TA416: Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer
 

View adult BNF  View SPC online  View childrens BNF  CDF
Pomalidomide
Restricted

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • See links below
    • Check MHRA Drugs Safety Updates
  • RFL:
    • As per NICE TAs
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).
    • Additionally for in-patients this drug must be prescribed on an in-patients prescription chart (paper or electronic)
      Patient, prescriber and supplying pharmacy must comply with a pregnancy prevention programme
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • See links below
Link  NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib
 

Restricted Drug View adult BNF  View SPC online  View childrens BNF  HCD  CDF
Teriflunomide
Restricted

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal but is not listed in the Trust Medicines Formulary as the service is not offered at NMUH.
  • RFL:
    • As per NICE TA
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
Link  NICE TA303: Teriflunomide for relapsing remitting MS
Link  NICE TA405:Trifluridine–tipiracil for previously treated metastatic colorectal cancer
 

Restricted Drug View adult BNF  View SPC online  View childrens BNF  HCD
Thalidomide
Restricted

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • This medicine has a positive NICE Technology Appraisal and is listed in the Trust Medicines Formulary when used in line with NICE recommendations and/or Local Trust Guidelines.
    • Check MHRA Drug Safety Alerts
  • RFL:
    • As per NICE TA
    • This drug for the treatment of malignant disease must be prescribed on chemocare (RFL electronic chemotherapy prescribing system).  Additionally for in-patients this drug must be prescribed on an in-patients prescription chart (paper or electronic)
    • Patient, prescriber and supplying pharmacy must comply with a pregnancy prevention programme
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • The use of thalidomide is restricted to Consultant Haematologists for the treatment of end-stage myeloma.
Link  NICE TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma
 

Restricted Drug GP - Red View adult BNF  View SPC online  View childrens BNF  HCD
Cediranib Recentin®
Non Formulary

View adult BNF  View SPC online  View childrens BNF
Dinutuximab beta injection
Non Formulary

See NICE TA for eligibility criteria

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
Link  NICE TA538: Dinutuximab beta for treating neuroblastoma
 

View adult BNF  View SPC online  View childrens BNF
Pemrolizumab Keytruda®
Non Formulary

View adult BNF  View SPC online  View childrens BNF
Siltuximab
Non Formulary

View adult BNF  View SPC online  View childrens BNF